Shareholder litigation law firm Kaskela Law is investigating the fairness of the recently announced buyout of Select Medical Holdings Corp. (NYSE: SEM) (“Select Medical”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their shares.
Click here to register for additional information about this investigation: https://kaskelalaw.com/case/select-medical/
On March 2, 2026, Select Medical announced that it had agreed to be acquired by an investment consortium at a price of $16.50 per share in cash. Upon completion of the transaction, Select Medical’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded.
The investigation seeks to determine whether Select Medical investors will receive sufficient monetary consideration for their shares, and whether the company's officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to the $16.50 per share buyout price. Notably, at the time the proposed transaction was announced, at least one stock analyst was maintaining a price target for Select Medical’s shares of $19.00 per share.
Select Medical shareholders who think the buyout price is too low are encouraged to contact lead investigative attorney Adrienne Bell, Esquire at (484) 229 – 0750, by email at abell@kaskelalaw.com, or by filling out the online form at:
https://kaskelalaw.com/case/select-medical/
ABOUT KASKELA LAW:
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm’s clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com.
This communication may constitute attorney advertising in certain jurisdictions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260604776465/en/
This investigation seeks to determine whether Select Medical investors will be receiving sufficient monetary consideration for their shares.
Contacts
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com
